The Most Common Cutaneous Side Effects of Epidermal Growth Factor Receptor Inhibitors and Their Management

摘要: The use of epidermal growth factor receptor inhibitors (EGFRI) for the treatment solid tumors is increasing due to elevated expression receptors (EGFR) in stimulation tumor development. EGFR have shown be effective neoplasms head, neck, colon, and lung. Inhibition may cause cutaneous reactions more than 50% patients. most common skin manifestations are papulopustular lesions seborrhoeic areas (upper torso, face, scalp). Other side effects include xerosis hair nail changes. onset eruption usually within one three weeks after starting therapy, although some cases it occur much later. All dermatologic reversible generally resolve adequate therapy. However, a minority patients severe intolerable, demanding dose reduction or even interruption A positive correlation has been demonstrated between degree toxicity antitumor response. For dermatologists goal provide symptoms, so that patient continue benefit from EGFRI frequent manifestations, though related better response, limit therapy considering interference with quality life. Early management prevent severe, extensive need reduction, interruption. This indicates dermatologist should play role early stages treatment.